We cut short feeding duration for petty things like career, beauty and money.
We also don’t have access to ethically procured A2 milk from lovable mother Gau.
Mother’s milk has HAMLET. Cow’s raw milk has BAMLET.
Both can control cancerous nature of the cell.
And we cry increasing numbers of cancer cases. 🙁
“Breast-feeding has also been reported to protect against development of immunological diseases, such as allergy (Ahmed & Fuchs, 1997; Saarinen & Kajosaari, 1995), infantile diabetes mellitus (Gerstein, 1994; Mayer et al., 1988) and inflammatory gastrointestinal disease (Koletzko et al., 1989). These results imply that factors in milk may help optimise the function of the immune system and regulate cell populations that results in les risk of tumor development and less risk for abberant immunity in the rapidly growing neonatal intestinal tract.”
“These data indicate that BAMLET triggers lysosomal cell death pathway in cancer cells, thereby clarifying the ability of alpha-lactalbumin:oleate complexes to kill highly apoptosis-resistant tumor cells.”
Breast-feeding, HAMLET, and cancer
HAMLETs effect against tumors in vivo
To date several studies have addressed the ability of HAMLET to kill tumor cells in vivo. Early attempts in mouse models were thwarted as we realized that serum (especially serum albumin) induces a partial inactivation of HAMLET based on binding to the fatty acid in HAMLET. The attempts that have since been done have addressed topical or mucosal administration of HAMLET.
Walter Fischer, then in Bergen, Norway, used HAMLET in a model where tumor tissue from patients with glioblastomas were transplanted under the skull of rats. In this model one dose of HAMLET was infused in the brain through a pump and tissue was tested for apoptosis induction and the rats were monitored for survival. HAMLET treatment delayed death of the rats and the most important finding was that when investigating the brain tissue they found that apoptosis was only induced in tumor cells, no healthy brain cells were affected (Fischer Cancer Res 2004). This indicated what we already know in vitro, that the protein only attacks tumor cells, and indicated that little side effects may be expected should this be used for treatment purposes. Walter, now in Copenhagen, Denmark, is currently planning a patient study in patients with glioblastomas.
In a second study, Lotta Gustafsson together with Irene Leijonhufvud conducted a study on benign papilloma virus warts. Papillomas are a benign tumor form where the skin cells are transformed by virus infection and the hypothesis was that this transformation may make them susceptible to HAMLET treatment. A population of individuals having a major problem with recurrent warts were treated topically with HAMLET and it was found that HAMLET was effective in eliminating warts and that this effect had a long lasting effect (Gustafsson NEJM 2004).
Recently, Anki Mossberg together with Bjorn Wullt performed a study on 9 patients with transitional bladder carcinomas (tumor of the urinary bladder) (Mossberg Int J Cancer 2007). They instilled HAMLET in the bladder of patients in the week preceding surgery and evaluated the tumor morphology by endoscopic photography and apoptosis-induction in biopsy tissue. They found that a reduction in tumor size was seen in 8 of 9 patients and that apoptosis was detected in the tumor tissue but not in the adjacent healthy tissue, indicating that HAMLET is specifically tumorigenic also in vivo. This study was followed up by a study in mice (Mossberg, J Urol, 2010) using the MB49 bladder carcinoma model. In this model they showed a delay in tumor development when HAMLET was instilled in the bladder.
In a study from 2014 Puthia et al (Gut January issue, 2014) it wa shown that HAMLET could be used to prevent and treat colon cancer in APC/Min-mice. HAMLET was given perorally and showed a reduced progression of tumor growth and an increased survival when given as a prophylaxis and reduction of established tumors when given as treatment. HAMLEt accumulated only in tumor tissue and only healthy cells were observed to be apoptotic.
BAMLET activates a lysosomal cell death program in cancer cells.
A complex of human alpha-lactalbumin and oleic acid (HAMLET) was originally isolated from human milk as a potent anticancer agent. It kills a wide range of transformed cells of various origins while leaving nontransformed healthy cells largely unaffected both in vitro and in vivo. Importantly, purified alpha-lactalbumins from other mammals form complexes with oleic acid that show biological activities similar to that of HAMLET. The mechanism by which these protein-lipid complexes kill tumor cells is, however, largely unknown. Here, we show that complex of bovine alpha-lactalbumin and oleic acid (BAMLET), the bovine counterpart of HAMLET, kills tumor cells via a mechanism involving lysosomal membrane permeabilization. BAMLET shows potent cytotoxic activity against eight cancer cell lines tested, whereas nontransformed NIH-3T3 murine embryonic fibroblasts are relatively resistant. BAMLET accumulates rapidly and specifically in the endolysosomal compartment of tumor cells and induces an early leakage of lysosomal cathepsins into the cytosol followed by the activation of the proapoptotic protein Bax. Ectopic expression of three proteins known to stabilize the lysosomal compartment, i.e. heat shock protein 70 (Hsp70), Hsp70-2, and lens epithelium-derived growth factor, confer significant protection against BAMLET-induced cell death, whereas the antiapoptotic protein Bcl-2, caspase inhibition, and autophagy inhibition fail to do so. These data indicate that BAMLET triggers lysosomal cell death pathway in cancer cells, thereby clarifying the ability of alpha-lactalbumin:oleate complexes to kill highly apoptosis-resistant tumor cells.